EPS100Momentum's  Instablog

EPS100Momentum
Send Message
Author has a degree in Engineering and is an avid investor in the market. Experience in industrial materials and structures. In college studied atomic & nuclear physics as well as material engineering. Eastern European
My blog:
EPS100Momentum's Instablog at SeekingAlpha
  • 10K filing by OSIR shows it can help Japan with Radiation exposure treatment. 2 comments
    Mar 16, 2011 8:54 AM | about stocks: OSIR, CBLI, AMGN, SNY, PFE, LLY, DNDN

    A partial from 10k Filing :

    In 2007, we partnered with Genzyme to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. In the first quarter of 2008, we were awarded a contract from the United States Department of Defense ("DoD") pursuant to which we, in partnership with Genzyme, are seeking to develop and stockpile Prochymal for the repair of gastrointestinal injury resulting from acute radiation exposure. Under the terms of the contract, the DoD will provide funding to us, and if we are successful in obtaining FDA approval for acute radiation syndrome, the contract provides for the purchase of up to 20,000 doses of Prochymal, at $10,000 per dose. Under the terms of this contract, we recognized $470,000 in revenue in fiscal 2010, $2.9 million in revenue in fiscal 2009, and $2.5 million in revenue in fiscal 2008.

    Filing link

    Note: OSIR shares have not moved as of yet on Japanese radiation, shares trading currently at $6.38 and in fact were much higher just a couple of months ago at $8.50 in mid Dec. 2010. So if investors get any hint like this 10K filing from Monday which was made available for our viewing today then it would not be surprising if (NASDAQ:OSIR) shares make its way back to $8.50 levels.

    Stocks: OSIR, CBLI, AMGN, SNY, PFE, LLY, DNDN
Back To EPS100Momentum's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (2)
Track new comments
  • ripper94
    , contributor
    Comments (9) | Send Message
     
    uhh yeah the contract awarded because of connection with ex military generals on osir board. this drug hasnt even been proved to work in this scenario. so why invest until they show tests from any phase suggesting that its stem cells are actually working and repairing the damage?
    16 Mar 2011, 10:58 AM Reply Like
  • pslice84
    , contributor
    Comments (323) | Send Message
     
    he also failed to mention that the payouts so far have been absolutely miniscule. A measly $6m. Hilarious.

     

    " In 2007, we partnered with Genzyme to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. In January 2008, we were awarded a contract from the United States Department of Defense ("DoD") pursuant to which we, in partnership with Genzyme, are seeking to develop and stockpile Prochymal for the repair of gastrointestinal injury resulting from acute radiation exposure. We began recognizing revenue under this contract during the first quarter of 2008. Contract revenue is recognized as the related costs are incurred, in accordance with the terms of the contract. We recognized approximately $470,000, $3.0 million, and $2.5 million in revenue from the DoD contract during 2010, 2009 and 2008, respectively."
    7 Apr 2011, 11:58 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.